Session 7: Beyond pathology of breast cancer in 2015
Chairs: Giuseppe Viale (Italy), Hervé Bonnefoi (France)
- The special case of “equivocal” pathological biomarkers (ER, PgR and HER2): Implications for breast cancer treatment (Fraser W. Symmans, USA)
- BCL-2: A new therapeutic target in estrogen receptor-positive breast cancer? (Geoffrey J. Lindeman, Australia)
- The changing role of ER in endocrine resistance (C. Kent Osborne, USA)
- Developing Ki-67 as a useful marker (Carsten Denkert, Germany)
- Discussion